About

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes. The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and de

Position in the VCSift Database

  • 3,884 investors in VCSift focus on the healthtech sector.
  • 62 investors are based in Rockville, Maryland, United States.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Stages
growth

Contact Information

Cu•••••••••••••@OpGen.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like OpGen

Search Investors